Cargando…

NIAID resources for developing new therapies for severe viral infections

Severe viral infections, including hemorrhagic fever and encephalitis, occur throughout the world, but are most prevalent in developing areas that are most vulnerable to infectious diseases. Some of these can also infect related species as illustrated by the threatened extinction of gorillas by Ebol...

Descripción completa

Detalles Bibliográficos
Autores principales: Greenstone, Heather, Spinelli, Beth, Tseng, Christopher, Peacock, Susan, Taylor, Katherine, Laughlin, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132394/
https://www.ncbi.nlm.nih.gov/pubmed/18061283
http://dx.doi.org/10.1016/j.antiviral.2007.10.006
_version_ 1783517427476201472
author Greenstone, Heather
Spinelli, Beth
Tseng, Christopher
Peacock, Susan
Taylor, Katherine
Laughlin, Catherine
author_facet Greenstone, Heather
Spinelli, Beth
Tseng, Christopher
Peacock, Susan
Taylor, Katherine
Laughlin, Catherine
author_sort Greenstone, Heather
collection PubMed
description Severe viral infections, including hemorrhagic fever and encephalitis, occur throughout the world, but are most prevalent in developing areas that are most vulnerable to infectious diseases. Some of these can also infect related species as illustrated by the threatened extinction of gorillas by Ebola infection in west and central Africa. There are no safe and effective treatments available for these serious infections. In addition to the logistical difficulties inherent in developing a drug for infections that are sporadic and occur mainly in the third world, there is the overwhelming barrier of no hope for return on investment to encourage the pharmaceutical industry to address these unmet medical needs. Therefore, the National Institute of Allergy and infectious Disease (NIAID) has developed and supported a variety of programs and resources to provide assistance and lower the barrier for those who undertake these difficult challenges. The primary programs relevant to the development of therapies for severe viral infections are described and three case studies illustrate how they have been used. In addition, contact information for accessing these resources is supplied.
format Online
Article
Text
id pubmed-7132394
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-71323942020-04-08 NIAID resources for developing new therapies for severe viral infections Greenstone, Heather Spinelli, Beth Tseng, Christopher Peacock, Susan Taylor, Katherine Laughlin, Catherine Antiviral Res Article Severe viral infections, including hemorrhagic fever and encephalitis, occur throughout the world, but are most prevalent in developing areas that are most vulnerable to infectious diseases. Some of these can also infect related species as illustrated by the threatened extinction of gorillas by Ebola infection in west and central Africa. There are no safe and effective treatments available for these serious infections. In addition to the logistical difficulties inherent in developing a drug for infections that are sporadic and occur mainly in the third world, there is the overwhelming barrier of no hope for return on investment to encourage the pharmaceutical industry to address these unmet medical needs. Therefore, the National Institute of Allergy and infectious Disease (NIAID) has developed and supported a variety of programs and resources to provide assistance and lower the barrier for those who undertake these difficult challenges. The primary programs relevant to the development of therapies for severe viral infections are described and three case studies illustrate how they have been used. In addition, contact information for accessing these resources is supplied. Elsevier 2008-04 2007-11-09 /pmc/articles/PMC7132394/ /pubmed/18061283 http://dx.doi.org/10.1016/j.antiviral.2007.10.006 Text en Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Greenstone, Heather
Spinelli, Beth
Tseng, Christopher
Peacock, Susan
Taylor, Katherine
Laughlin, Catherine
NIAID resources for developing new therapies for severe viral infections
title NIAID resources for developing new therapies for severe viral infections
title_full NIAID resources for developing new therapies for severe viral infections
title_fullStr NIAID resources for developing new therapies for severe viral infections
title_full_unstemmed NIAID resources for developing new therapies for severe viral infections
title_short NIAID resources for developing new therapies for severe viral infections
title_sort niaid resources for developing new therapies for severe viral infections
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132394/
https://www.ncbi.nlm.nih.gov/pubmed/18061283
http://dx.doi.org/10.1016/j.antiviral.2007.10.006
work_keys_str_mv AT greenstoneheather niaidresourcesfordevelopingnewtherapiesforsevereviralinfections
AT spinellibeth niaidresourcesfordevelopingnewtherapiesforsevereviralinfections
AT tsengchristopher niaidresourcesfordevelopingnewtherapiesforsevereviralinfections
AT peacocksusan niaidresourcesfordevelopingnewtherapiesforsevereviralinfections
AT taylorkatherine niaidresourcesfordevelopingnewtherapiesforsevereviralinfections
AT laughlincatherine niaidresourcesfordevelopingnewtherapiesforsevereviralinfections